Fundraising Fox
SLAM BioTherapeutics
Thousand Oaks, US · Founded 2022 · Delaware corporation
Find your way into SLAM BioTherapeutics
Sign up to see every warm intro you have to SLAM BioTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SLAM BioTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SLAM BioTherapeutics is a preclinical-stage biotech developing first-in-class antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the SLAM family of immune receptors (notably CD84/SLAMF5) for blood cancers such as MDS, AML, CTCL, and follicular lymphoma. Its lead asset SLM124 is planned to enter Phase 1 clinical trials in 2026, serving patients with hard-to-treat hematologic malignancies.
Founders & leadership
SLAM BioTherapeutics was founded in 2022 by Rick Heinick, Dr. Steven Rosen, and Idit Shachar.
RH
Rick HeinickCEO & Chairman, Co-founderHe has experience as a venture investor and strategic advisor in pharmaceutical and medical device companies.
DS
Dr. Steven RosenCo-Founder & SAB Chair
IS
Idit ShacharCo-Founder
CW
Chan WhitingChief Scientific OfficerChan Whiting is Chief Scientific Officer of SLAM BioTherapeutics, a biotech company developing antibody-drug conjugates and bispecific antibodies for blood cancers. He brings over 20 years of experience in immunology and oncology drug development, with expertise spanning target identification, therapeutic modality selection, preclinical and translational science, and regulatory pathways through multiple IND filings.
SP
Steve PottsNamed on SEC filing
Board
DV
David VennettilliBoard director
SP
Steve PazolBoard director
TS
Theodore SchwartzBoard director
MH
Mark HaglerBoard director
Reported raises · per SEC filings
Form D private placements$9.2M disclosed across 3 rounds · 2023–2025
▶$1MraisedDec 2025 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard HeinickExecutive Officer, Director
- Ted SchwartzDirector
- Steve PazolDirector
- Mark HaglerDirector
- David VennettilliDirector
- Offering amount
- $4M
- Amount sold
- $1M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$500KraisedMar 2025 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedMar 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David VennettilliDirector
- Theodore SchwartzDirector
- Steve PottsExecutive Officer, Director
- Mark HaglerDirector
- Richard HeinickExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $500K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$7.7MraisedNov 2023 · 38 investors · BiotechnologyRule 506(b)
▶$7.7MraisedNov 2023 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve PazolDirector
- Richard HeinickExecutive Officer, Director
- Mark HaglerDirector
- Offering amount
- $20M
- Amount sold
- $7.7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dispatch BiotherapeuticsDispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
Companies working in the same space as SLAM BioTherapeutics.
Frequently asked questions
- What does SLAM BioTherapeutics do?
- SLAM BioTherapeutics is a preclinical-stage biotech developing first-in-class antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the SLAM family of immune receptors (notably CD84/SLAMF5) for blood cancers such as MDS, AML, CTCL, and follicular lymphoma. Its lead asset SLM124 is planned to enter Phase 1 clinical trials in 2026, serving patients with hard-to-treat hematologic malignancies.
- Who founded SLAM BioTherapeutics?
- SLAM BioTherapeutics was founded by Rick Heinick, Dr. Steven Rosen, Idit Shachar in 2022.
- How much funding has SLAM BioTherapeutics raised?
- SLAM BioTherapeutics has disclosed $9.2M raised across 3 rounds.
- Where is SLAM BioTherapeutics headquartered?
- SLAM BioTherapeutics is headquartered in Thousand Oaks, US.